BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu CT, Chen MF, Chen WC, Hsieh CC. The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol. 2013;8:159. [PMID: 23806095 DOI: 10.1186/1748-717x-8-159] [Cited by in Crossref: 67] [Cited by in F6Publishing: 45] [Article Influence: 8.4] [Reference Citation Analysis]
Number Citing Articles
1 Gyamfi J, Eom M, Koo JS, Choi J. Multifaceted Roles of Interleukin-6 in Adipocyte-Breast Cancer Cell Interaction. Transl Oncol 2018;11:275-85. [PMID: 29413760 DOI: 10.1016/j.tranon.2017.12.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 12.3] [Reference Citation Analysis]
2 Miyata Y, Matsuo T, Sagara Y, Ohba K, Ohyama K, Sakai H. A Mini-Review of Reactive Oxygen Species in Urological Cancer: Correlation with NADPH Oxidases, Angiogenesis, and Apoptosis. Int J Mol Sci 2017;18:E2214. [PMID: 29065504 DOI: 10.3390/ijms18102214] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
3 Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Argyle DJ. Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness. Metabolites 2018;8:E13. [PMID: 29439394 DOI: 10.3390/metabo8010013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
4 Cha H, Lee EJ, Seong J. Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy. World J Gastroenterol 2017;23:2077-85. [PMID: 28373775 DOI: 10.3748/wjg.v23.i11.2077] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Centurione L, Aiello FB. DNA Repair and Cytokines: TGF-β, IL-6, and Thrombopoietin as Different Biomarkers of Radioresistance. Front Oncol 2016;6:175. [PMID: 27500125 DOI: 10.3389/fonc.2016.00175] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
6 Kale Ş, Korcum AF, Dündar E, Erin N. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 2020;393:253-62. [PMID: 31522240 DOI: 10.1007/s00210-019-01725-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Matsuoka Y, Nakayama H, Yoshida R, Hirosue A, Nagata M, Tanaka T, Kawahara K, Sakata J, Arita H, Nakashima H, Shinriki S, Fukuma D, Ogi H, Hiraki A, Shinohara M, Toya R, Murakami R. IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma. Br J Cancer 2016;115:1234-44. [PMID: 27736845 DOI: 10.1038/bjc.2016.327] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
8 Lee DS, O'Keefe RA, Ha PK, Grandis JR, Johnson DE. Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. Int J Mol Sci 2018;19:E1608. [PMID: 29848966 DOI: 10.3390/ijms19061608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ham IH, Oh HJ, Jin H, Bae CA, Jeon SM, Choi KS, Son SY, Han SU, Brekken RA, Lee D, Hur H. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Mol Cancer. 2019;18:68. [PMID: 30927911 DOI: 10.1186/s12943-019-0972-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 24.0] [Reference Citation Analysis]
10 Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 2015;7:967-80. [PMID: 26310908 DOI: 10.2217/imt.15.65] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 9.3] [Reference Citation Analysis]
11 Spitzner M, Ebner R, Wolff HA, Ghadimi BM, Wienands J, Grade M. STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy. Cancers (Basel) 2014;6:1986-2011. [PMID: 25268165 DOI: 10.3390/cancers6041986] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 8.7] [Reference Citation Analysis]
12 Galeaz C, Totis C, Bisio A. Radiation Resistance: A Matter of Transcription Factors. Front Oncol 2021;11:662840. [PMID: 34141616 DOI: 10.3389/fonc.2021.662840] [Reference Citation Analysis]
13 Bishop JL, Thaper D, Zoubeidi A. The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) 2014;6:829-59. [PMID: 24722453 DOI: 10.3390/cancers6020829] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 11.7] [Reference Citation Analysis]
14 Kim BM, Hong Y, Lee S, Liu P, Lim JH, Lee YH, Lee TH, Chang KT, Hong Y. Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy. Int J Mol Sci 2015;16:26880-913. [PMID: 26569225 DOI: 10.3390/ijms161125991] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 14.3] [Reference Citation Analysis]
15 Meng G, Wuest M, Tang X, Dufour J, Zhao Y, Curtis JM, McMullen TPW, Murray D, Wuest F, Brindley DN. Repeated Fractions of X-Radiation to the Breast Fat Pads of Mice Augment Activation of the Autotaxin-Lysophosphatidate-Inflammatory Cycle. Cancers (Basel) 2019;11:E1816. [PMID: 31752313 DOI: 10.3390/cancers11111816] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
16 Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234-248. [PMID: 29405201 DOI: 10.1038/nrclinonc.2018.8] [Cited by in Crossref: 667] [Cited by in F6Publishing: 602] [Article Influence: 222.3] [Reference Citation Analysis]
17 Dong YL, Vadla GP, Lu JJ, Ahmad V, Klein TJ, Liu LF, Glazer PM, Xu T, Chabu CY. Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance. Commun Biol 2021;4:374. [PMID: 33742110 DOI: 10.1038/s42003-021-01898-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Espinoza-Sánchez NA, Győrffy B, Fuentes-Pananá EM, Götte M. Differential impact of classical and non-canonical NF-κB pathway-related gene expression on the survival of breast cancer patients. J Cancer 2019;10:5191-211. [PMID: 31602271 DOI: 10.7150/jca.34302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
19 Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, Xing H, Xu Y, Shi J, Guo W, Zhou D, Zhang H, Sun H, Huang C, Lu C, Zheng Y, Meng Y, Huang B, Cong W, Lau WY, Cheng S. Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. J Clin Oncol 2019;37:2141-51. [PMID: 31283409 DOI: 10.1200/JCO.18.02184] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 19.5] [Reference Citation Analysis]
20 Singh J, Sohal SS, Lim A, Duncan H, Thachil T, De Ieso P. Cytokines expression levels from tissue, plasma or serum as promising clinical biomarkers in adenocarcinoma of the prostate: a systematic review of recent findings. Ann Transl Med 2019;7:245. [PMID: 31317015 DOI: 10.21037/atm.2019.05.31] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Singh J, Sohal SS, Ahuja K, Lim A, Duncan H, Thachil T, De Ieso P. Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate. Ann Transl Med 2020;8:636. [PMID: 32566573 DOI: 10.21037/atm-19-1913] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Arnold KM, Flynn NJ, Raben A, Romak L, Yu Y, Dicker AP, Mourtada F, Sims-Mourtada J. The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules. Cancer Growth Metastasis. 2018;11:1179064418761639. [PMID: 29551910 DOI: 10.1177/1179064418761639] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 17.0] [Reference Citation Analysis]
23 Chen Y, Zhang F, Tsai Y, Yang X, Yang L, Duan S, Wang X, Keng P, Lee SO. IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation. Radiat Oncol 2015;10:227. [PMID: 26572130 DOI: 10.1186/s13014-015-0534-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
24 Narayan V, Thompson EW, Demissei B, Ho JE, Januzzi JL Jr, Ky B. Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:2726-37. [PMID: 32466889 DOI: 10.1016/j.jacc.2020.03.067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
25 Wu CT, Huang YC, Chen WC, Chen MF. Effect of 1α,25-Dihydroxyvitamin D3 on the Radiation Response in Prostate Cancer: Association With IL-6 Signaling. Front Oncol 2021;11:619365. [PMID: 34109109 DOI: 10.3389/fonc.2021.619365] [Reference Citation Analysis]
26 Anker JF, Naseem AF, Mok H, Schaeffer AJ, Abdulkadir SA, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 2018;9:1591. [PMID: 29686284 DOI: 10.1038/s41467-018-03900-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 10.7] [Reference Citation Analysis]
27 Lu G, Tian S, Sun Y, Dong J, Wang N, Zeng J, Nie Y, Wu K, Han Y, Feng B, Shang Y. NEK9, a novel effector of IL-6/STAT3, regulates metastasis of gastric cancer by targeting ARHGEF2 phosphorylation. Theranostics 2021;11:2460-74. [PMID: 33500736 DOI: 10.7150/thno.53169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wennerberg E, Vanpouille-Box C, Bornstein S, Yamazaki T, Demaria S, Galluzzi L. Immune recognition of irradiated cancer cells. Immunol Rev 2017;280:220-30. [PMID: 29027232 DOI: 10.1111/imr.12568] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
29 Di Maggio FM, Minafra L, Forte GI, Cammarata FP, Lio D, Messa C, Gilardi MC, Bravatà V. Portrait of inflammatory response to ionizing radiation treatment. J Inflamm (Lond) 2015;12:14. [PMID: 25705130 DOI: 10.1186/s12950-015-0058-3] [Cited by in Crossref: 134] [Cited by in F6Publishing: 102] [Article Influence: 22.3] [Reference Citation Analysis]
30 Shen MJ, Xu LJ, Yang L, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y. Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway. Oncotarget 2017;8:80506-20. [PMID: 29113321 DOI: 10.18632/oncotarget.19193] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
31 Yang J, Xu T, Gomez DR, Yuan X, Nguyen QN, Jeter M, Song Y, Komaki R, Hu Y, Hahn SM, Liao Z. Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer. Cancer Med 2018;7:2247-55. [PMID: 29745043 DOI: 10.1002/cam4.1349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Huang W, Fan Y, Cheng X, Liang H, Pan H, Xiao T, Chen M, Guan J. A preliminary Study on the Effect of Head and Neck Chemoradiotherapy on Systematic Immunity. Dose Response 2019;17:1559325819884186. [PMID: 31695581 DOI: 10.1177/1559325819884186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lau YK, Ramaiyer M, Johnson DE, Grandis JR. Targeting STAT3 in Cancer with Nucleotide Therapeutics. Cancers (Basel) 2019;11:E1681. [PMID: 31671769 DOI: 10.3390/cancers11111681] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
34 Yang PL, Liu LX, Li EM, Xu LY. STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy. Cancers (Basel) 2020;12:E2459. [PMID: 32872659 DOI: 10.3390/cancers12092459] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
35 Kumar R, de Mooij T, Peterson TE, Kaptzan T, Johnson AJ, Daniels DJ, Parney IF. Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane. PLoS One 2017;12:e0179012. [PMID: 28666020 DOI: 10.1371/journal.pone.0179012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
36 Lupu-Plesu M, Claren A, Martial S, N'Diaye PD, Lebrigand K, Pons N, Ambrosetti D, Peyrottes I, Feuillade J, Hérault J, Dufies M, Doyen J, Pagès G. Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma. Oncogenesis 2017;6:e354. [PMID: 28671677 DOI: 10.1038/oncsis.2017.56] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
37 Harmer D, Falank C, Reagan MR. Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma.Front Endocrinol (Lausanne). 2018;9:788. [PMID: 30671025 DOI: 10.3389/fendo.2018.00788] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 26.0] [Reference Citation Analysis]
38 Tamari Y, Kashino G, Mori H. Acquisition of radioresistance by IL-6 treatment is caused by suppression of oxidative stress derived from mitochondria after γ-irradiation. J Radiat Res 2017;58:412-20. [PMID: 28199717 DOI: 10.1093/jrr/rrw084] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
39 Rath BH, Wahba A, Camphausen K, Tofilon PJ. Coculture with astrocytes reduces the radiosensitivity of glioblastoma stem-like cells and identifies additional targets for radiosensitization. Cancer Med 2015;4:1705-16. [PMID: 26518290 DOI: 10.1002/cam4.510] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
40 West AJ, Tsui V, Stylli SS, Nguyen HPT, Morokoff AP, Kaye AH, Luwor RB. The role of interleukin-6-STAT3 signalling in glioblastoma. Oncol Lett 2018;16:4095-104. [PMID: 30250528 DOI: 10.3892/ol.2018.9227] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
41 Li F, Wei L, Li S, Liu J. Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer. Oncotarget. 2017;8:107844-107858. [PMID: 29296206 DOI: 10.18632/oncotarget.22253] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
42 Ebbing EA, van der Zalm AP, Steins A, Creemers A, Hermsen S, Rentenaar R, Klein M, Waasdorp C, Hooijer GKJ, Meijer SL, Krishnadath KK, Punt CJA, van Berge Henegouwen MI, Gisbertz SS, van Delden OM, Hulshof MCCM, Medema JP, van Laarhoven HWM, Bijlsma MF. Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. Proc Natl Acad Sci U S A 2019;116:2237-42. [PMID: 30670657 DOI: 10.1073/pnas.1820459116] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 24.0] [Reference Citation Analysis]
43 Sabol RA, Villela VA, Denys A, Freeman BT, Hartono AB, Wise RM, Harrison MAA, Sandler MB, Hossain F, Miele L, Bunnell BA. Obesity-Altered Adipose Stem Cells Promote Radiation Resistance of Estrogen Receptor Positive Breast Cancer through Paracrine Signaling. Int J Mol Sci 2020;21:E2722. [PMID: 32326381 DOI: 10.3390/ijms21082722] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
44 Zong Z, Wei Y, Ren J, Zhang L, Zhou F. The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Mol Cancer 2021;20:76. [PMID: 34001144 DOI: 10.1186/s12943-021-01363-1] [Reference Citation Analysis]
45 Yang X, Shi B, Li L, Xu Z, Ge Y, Shi J, Liu Y, Zheng D. Death receptor 6 (DR6) is required for mouse B16 tumor angiogenesis via the NF-κB, P38 MAPK and STAT3 pathways. Oncogenesis 2016;5:e206. [PMID: 26950598 DOI: 10.1038/oncsis.2016.9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]